NFKB1 and chronic obstructive pulmonary disease: Indeed, Sirt4 inhibits the degradation of IκBα, an inhibitor of NfκB [98] preventing the activation of the inflammatory cascade and acting along its pathway may represent a novel therapeutic approach to COPD progression.